An outcome that represents the patient voice evaluating the symptomatic treatment related adverse events for people with rheumatic and musculoskeletal diseases enrolled in clinical trials.
This would include severity, frequency, and interference of symptoms (i.e., distinct from ‘signs’) from different body systems.
